Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ative new study, a University of Utah scientist ar...or cause of global warming cannot be stabilized u...lds the equivalent of one new nuclear power plant ...be any substantial near-term departure from recent...n rates," says the new paper by Tim Garrett, an as...
(Date:11/23/2009)...nication, computation and more powerful ways to en...ntum states as carriers of information is an extre...own, mathematically, how to gently tease out unwan...the information intact. Their work is reported in ... highlighted with a Viewpoint in Physics ( http:...
(Date:11/23/2009)...-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDLI )...009astheex-dividenddateforits$200millionspecialdiv...ransactioncompletedonNovember2,2009.Thedividendwil...ntherecorddate,December1,2009.NASDAQhassettheappro...commonstockforpurposesoftheex-dividenddateonNovemb...
(Date:11/23/2009)...Call/--NeogenCorporation(Nasdaq: NEOG )announcedto...BoardofDirectorsatthecompany,srecentannualmeetingo...perienceinthefood,agriculture,andtradeindustriesan...economicsatVirginiaTechUniversity.FromJanuary2006u...negotiatorwiththerankofambassador. ,, "Sinceour...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Richard T. Crowder Joins Neogen's Board of Directors 2
... The International,Confocal Microscopy Working Gro...and students, has been formed as a means to promot...onfocal microscopy (RCM) in,patient care., The Wo...dwide.,Dermatologists, dermascopists, dermatopatho...interested in learning more about RCM should consi...
...e Therapeutics,Inc. (OTC Bulletin Board: NILT.OB),... therapies for cardiovascular disease, is pleased ...., F.A.C.C. as its Vice President of,Clinical Rese...e. Dr. Lieu has extensive,cardiovascular clinical ...y,beneficial to Nile and our CD-NP and 2NTX-99 dev...
... Strativa,Pharmaceuticals, the proprietary product...rmaceutical Companies, Inc. (NYSE: PRX ) today,an...maceuticals, Inc.,(Amex: IMM ) has chosen to disc...aleate, an investigative therapy., On February 22...itional,reports of adverse events related to abnor...
Other Biology Technology:International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy 2Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 2Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 3Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 2Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 3
(Date:11/23/2009)...ridge, Mass. November 23, 2009 Applied mathemati...y ( Hosta lancifolia ), a characteristic long leaf...ked ripples along the edges. The simple cause of t...ng from bending during differential growthwas reve...ing foam ribbons. , Haiyi Liang, a postdoctoral ...
(Date:11/23/2009)...IGN, Ill. A new study provides "incontrovertible ... on the island of Sumatra about 73,000 years ago d...from the epicenter, researchers report. , The vo... ash into the atmosphere, leaving a crater (now th...eters long and 35 kilometers wide. Ash from the ev...
(Date:11/23/2009)..., N.H. University of New Hampshire microbiologist...115 to advance understanding of the actinorhizal p...nrich nutrient-poor and contaminated soils. , T...awarded Tisa, a professor of molecular, cellular a...mbiotic relationship between the bacteria Frankia ...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2UNH prof. receives nearly $500,000 to research environmentally significant plants 2Expensive Health Care 3A Undetected Unmet Mobility Needs Creating Boomer 26 Senior Health Care Costs 54289 1Expensive Health Care 3A Undetected Unmet Mobility Needs Creating Boomer 26 Senior Health Care Costs 54289 2Frost 26 Sullivan 3A Outsourcing Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 54286 1Frost 26 Sullivan 3A Outsourcing Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 54286 2Frost 26 Sullivan 3A Outsourcing Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 54286 3American Nurses Association Joins the National Healthcare Career Network 54285 1American Nurses Association Joins the National Healthcare Career Network 54285 2American Nurses Association Joins the National Healthcare Career Network 54285 3
...A protein that causes coral to glow is helping res...edicine to light up brain cells that are critical ...system. This fluorescent marker protein may shed l... in various neurological diseases. The researchers...ember 20, 2006, issue of The Journal of Neuroscien...
...Mayo Clinic Cancer Center has opened a new Phase I...s against multiple myeloma, a cancer of the bone m...d of a series of molecular medicine studies in pat...cer. , “This is the beginning of a long but excit...logist and lead researcher on the multiple myeloma...
...Returning from a recent 1,000-mile expedition acro...ervation Society (WCS) biologist George Schaller r...t of rampant poaching -- may be increasing in numb... a growing conservation ethic in local communities... WCS and National Geographic, took place over a re...
Other Biology News:Researchers develop marker that identifies energy-producing centers in nerve cells 2Investigating the measles virus as a tool to kill multiple myeloma 2Investigating the measles virus as a tool to kill multiple myeloma 3Tibetan antelope slowly recovering, WCS says 2
Corning 96 Well Eia/Ria Microplate,Flat Bottom,Med Binding,Non-Sterile,W/O Lid from Sigma-Aldrich
...ss-to-seal gasket and cover slip enclosures which ...idizing and imaging thick or free floating specime...uild up to three chambers per slide. Minimize spec...ven when submerged. RNase-free, ready to use for m...
Secure-Seal hybridization chambers from Sigma-Aldrich
LC-NMR-MSn system from Bruker Daltonics
Biology Products: